UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 12B-25

                        COMMISSION FILE NUMBER-000-23399

                           NOTIFICATION OF LATE FILING

(CHECK  ONE)
 X  FORM  10-K  AND  FORM  10-KSB __ FORM 20-F  __ FORM 11-K
__ FORM 10-Q AND FORM 10-QSB __  FORM N-SAR

          FOR  PERIOD  ENDED  JULY  31,  2002
                             -----------------
     __  TRANSITION  REPORT  ON  FORM  10-K  AND  FORM  10-KSB
     __  TRANSITION  REPORT  ON  FORM  20-F
     __  TRANSITION  REPORT  ON  FORM  11-K
     __  TRANSITION  REPORT  ON  FORM  10-Q  AND  FORM  10-QSB
     __  TRANSITION  REPORT  ON  FORM  N-SAR
     FOR  THE  TRANSITION  PERIOD  ENDED: ____________________

             READ INSTRUCTIONS (ON BACK PAGE) BEFORE PREPARING FORM.
                              PLEASE PRINT OR TYPE.
     NOTHING  IN  THIS  FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS
VERIFIED  ANY  INFORMATION  CONTAINED  HEREIN.

     IF  THE  NOTIFICATION  RELATES  TO  A  PORTION OF THE FILING CHECKED ABOVE,
IDENTIFY  THE  ITEM(S)  TO  WHICH  THE  NOTIFICATION  RELATES:  _______________
_______________________________________________________________________________

PART  I--REGISTRANT  INFORMATION

Full  Name  of  Registrant:  NOVADEL  PHARMA  INC.
                             ---------------------

Former  Name  of  Registrant:  FLEMINGTON  PHARMACEUTICAL  CORPORATION
                               ---------------------------------------

Address  of  Principal  Executive  Office  (Street  and  Number):

31 STATE HIGHWAY 12, FLEMINGTON, NJ  08822
------------------------------------------



PART  II--RULES  12B-25(b)  AND  (c)

If  the subject report could not be filed without unreasonable effort or expense
and  the  registrant seeks relief pursuant to Rule 12b-25b, the following should
be  completed.  (Check  box  if  appropriate):

[X]     (a)     The  reasons  described in reasonable detail in Part III of this
form  could  not  be  eliminated  without  unreasonable  effort  or  expense;
[X]     (b)     The subject annual report, semi-annual report, transition report
on  Forms 10-K, 10-KSB, Form 20-F, 11-K, Form N-SAR, or portion thereof, will be
filed on or before the fifteenth calendar day following the prescribed due date;
or  the  subject quarterly report or transition report on Forms 10-Q, 10-QSB, or
portion  thereof will be filed on or before the fifth calendar day following the
prescribed  due  date;  and
[  ]     (c)     The  accountant's  statement  or other exhibit required by Rule
12b-25(c)  has  been  attached  if  applicable.

PART  III--NARRATIVE

State  below  in reasonable detail the reasons why the Forms 10-K, 10-KSB, 20-F,
11-K, 10-Q,10-QSB, N-SAR, or the transition report or portion thereof, could not
be  filed  within  the  prescribed  time period. (ATTACH EXTRA SHEETS IF NEEDED)

     The  Company  has not been able to compile the requisite financial data and
other  narrative  information  necessary to enable it to have sufficient time to
complete  the  Company's  Annual  Report on Form 10-KSB by October 29, 2002, the
required  filing  date,  without  unreasonable  effort  and  expense.

PART  IV--OTHER  INFORMATION

(1)     Name  and  telephone  number  of  person  to  contact  in regard to this
notification

     Harry  A.  Dugger,  III           (908)               782-3431
     -----------------------        --------          -----------------
     (NAME)                        (AREA  CODE)      (TELEPHONE  NUMBER)

(2)     Have  all  other  periodic reports required under Section 13 or 15(d) of
the  Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
of  1940  during  the  preceding  12 months (or for such shorter period that the
registrant  was  required  to  file  such reports) been filed?  If answer is no,
identify  report(s).      X  Yes  No
                         --

(3)     Is  it  anticipated that any significant change in results of operations
from  the corresponding period for the last fiscal year will be reflected by the
earnings  statements  to  be  included in the subject report or portion thereof?
                                              Yes    X  No
                                                    ---
     If  so,  attach  an explanation of the anticipated change, both narratively
and  quantitatively,  and,  if  appropriate,  state the reasons why a reasonable
estimate  of  the  results  cannot  be  made.



                               NOVADEL PHARMA INC.
                               -------------------
                  (Name of Registrant as Specified In Charter)

has  caused  this  notification  to  be  signed on its behalf by the undersigned
hereto  duly  authorized

Dated:  October  28,  2002              NOVADEL  PHARMA  INC.



                                By:     /s/Harry  A.  Dugger,  III
                                       --------------------------
                                        Harry  A.  Dugger,  III,  President  and
                                        Chief  Executive  Officer


INSTRUCTION: The form may be signed by an executive officer of the registrant or
by  any  other duly authorized representative.  The name and title of the person
signing  the  form  shall  be  typed  or  printed beneath the signature.  If the
statement  is signed on behalf of the registrant by an authorized representative
(other than an executive officer), evidence of the representative's authority to
sign  on  behalf  of  the  registrant  shall  be  filed  with  the  form.

                                    ATTENTION
     INTENTION  MISSTATEMENTS  OR  OMISSIONS OF FACT CONSTITUTE FEDERAL CRIMINAL
VIOLATIONS  (SEE  18  U.S.C.  1001).

                              GENERAL INSTRUCTIONS

1.     This  form  is required by Rule 12b-25 (17 CFR 240.12b-25) of the General
Rules  and  Regulations  under  the  Securities  Exchange  Act  of  1934.

2.     One signed original and four conformed copies of this form and amendments
thereto must be completed and filed with the Securities and Exchange Commission,
Washington,  D.C.  20549,  in  accordance with Rule 0-3 of the General Rules and
Regulations  under the Act.  The information contained in or filed with the form
will  be  made  a  matter  of  public  record  in  the  Commission  files.

3.     A  manually signed copy of the form and amendments thereto shall be filed
with  each  national securities exchange on which any class of securities of the
registrant  is  registered.

4.     Amendments  to  the  notifications  must also be filed on form 12b-25 but
need  not restate information that has been correctly furnished.  The form shall
be  clearly  identified  as  an  amendment  notification.